Enalapril in the treatment of hypertension associated with impaired renal function.
This pilot study was undertaken to examine the safety and efficacy of enalapril in the treatment of hypertension associated with impaired renal function. Forty-one patients with glomerular filtration rate (GFR) < or = 50 ml/min received enalapril for up 12 weeks. Blood pressure, renal function, biochemistry and haematology were monitored weekly for 4 weeks and then monthly. Blood pressure was effectively reduced within 4 weeks; this reduction was maintained for at least 12 weeks. Renal function remained stable and there was no significant sustained alteration in any biochemical or haematological parameter. Requirement for additional antihypertensive drugs was reduced during enalapril therapy. These data suggest that enalapril may have a useful role in the management of hypertension associated with renal impairment.
Cooper
W D
WD
Merck Sharp and Dohme Limited, Hoddesdon, UK.
Doyle
G D
GD
Donohoe
J
J
Laher
M
M
Ledingham
J G
JG
Raine
A E
AE
Melinck
C
C
Unsworth
J
J
Raman
G V
GV
VandenBurg
M J
MJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects
D004656:Enalapril